duvakitug vs tulisokibart
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Ulcerative Colitis
Shared mechanism: TL1A · full Ulcerative Colitis pipeline
duvakitug
Developed by Teva Pharmaceutical Industries and partners
NCT05499130 · Phase 2b · completed
Randomized, double-blind, placebo-controlled dose-ranging basket study in UC and Crohn's disease. In UC the high dose separated from placebo on clinical remission (p=.003) and the low dose was borderline (p=.050); in Crohn's disease endoscopic response was 47.8% (high dose) and 26.1% (low dose) vs 13.0% placebo. The sponsor reports one-sided p-values at a 0.10 significance level, a lenient threshold, and each cohort was modest in size. A well-designed Phase 2b with a dose-dependent, partly borderline result is capped at moderate. Progressed to Phase 3.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: May 2028 · NCT07184996 (registry estimate)
Reported efficacy
Clinical remission (mMS) at week 14: UC cohort, clinical remission at week 14: 36% (450 mg) / 48% (900 mg) vs 20% placebo, placebo-adjusted 16% (p=.050) / 27% (p=.003). CD cohort, endoscopic response: 26.1% (low dose) / 47.8% (high dose) vs 13.0% placebo. P-values are one-sided at a 0.10 significance level. (met)
Result source: NCT05499130
tulisokibart
Developed by Merck & Co.
NCT06052059 · Phase 3 · active, not recruiting
First Ph3 induction win for any anti-TL1A; met primary + key secondaries (June 2026).
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: December 2037 · NCT06651281 (registry estimate)
Reported efficacy
Clinical remission (MMS) at week 12: ATLAS-UC Study 2 (NCT06052059): tulisokibart met its primary endpoint of clinical remission (Modified Mayo Score) at week 12, plus key secondary endpoints. (met)
Result source: NCT06052059
Results for Ulcerative Colitis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | duvakitug | tulisokibart |
|---|---|---|
| Clinical remission (induction) | 47.8% vs 20.5%+27.3 vs placeboNCT054991303 other results
| 26.5% vs 1.5%+25 vs placeboNCT049967971 other result
|
| Clinical remission (maintenance) | —Trial running · NCT07185009 | —Trial running · NCT06052059 |
| Clinical response (induction) | 69.6% vs 52.3%+17.3 vs placeboNCT054991303 other results
| 66.2% vs 22.4%+43.8 vs placeboNCT049967971 other result
|
| Endoscopic improvement (induction) | —Trial running · NCT07185009 | 36.8% vs 6%+30.8 vs placeboNCT049967971 other result
|
| Corticosteroid-free remission (maintenance) | —Trial running · NCT07185009 | —Trial running · NCT06052059 |
Clinical remission (induction)
- duvakitug
- 47.8% vs 20.5%+27.3 vs placeboNCT05499130
3 other results
- 36.2% vs 20.5% NCT05499130
- 23.9% vs 9.1% NCT05499130
- 29.8% vs 9.1% NCT05499130
- tulisokibart
- 26.5% vs 1.5%+25 vs placeboNCT04996797
1 other result
- 31.6% vs 10.8% NCT04996797
Clinical remission (maintenance)
- duvakitug
- —Trial running · NCT07185009
- tulisokibart
- —Trial running · NCT06052059
Clinical response (induction)
- duvakitug
- 69.6% vs 52.3%+17.3 vs placeboNCT05499130
3 other results
- 73.9% vs 50% NCT05499130
- 80.9% vs 52.3% NCT05499130
- 83% vs 50% NCT05499130
- tulisokibart
- 66.2% vs 22.4%+43.8 vs placeboNCT04996797
1 other result
- 55.3% vs 32.4% NCT04996797
Endoscopic improvement (induction)
- duvakitug
- —Trial running · NCT07185009
- tulisokibart
- 36.8% vs 6%+30.8 vs placeboNCT04996797
1 other result
- 36.8% vs 18.9% NCT04996797
Corticosteroid-free remission (maintenance)
- duvakitug
- —Trial running · NCT07185009
- tulisokibart
- —Trial running · NCT06052059
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. duvakitug: 4 of 4 rows · tulisokibart: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | duvakitug | tulisokibart |
|---|---|---|
| Dropout rate | 0%1800 mga NCT05499130 · Phase 2b · monotherapy show 5 more results0%1800 mg NCT05499130 · Phase 2b · monotherapy 8.5%900 mg NCT05499130 · Phase 2b · monotherapy 2.2%900 mg NCT05499130 · Phase 2b · monotherapy 19.6%450 mg NCT05499130 · Phase 2b · monotherapy 0%450 mg NCT05499130 · Phase 2b · monotherapy | —All Cohorts (Cohort 1 & Cohort 2) NCT04996797 · Phase 2 · Ulcerative Colitis · phase 2 show 1 more resultn/a: no completion milestoneCohort 1 Tulisokibart NCT04996797 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2 |
| Discontinued due to AEs | 0%1800 mga NCT05499130 · Phase 2b · monotherapy show 5 more results0%1800 mg NCT05499130 · Phase 2b · monotherapy 2.1%900 mg NCT05499130 · Phase 2b · monotherapy 2.2%900 mg NCT05499130 · Phase 2b · monotherapy 8.7%450 mg NCT05499130 · Phase 2b · monotherapy 0%450 mg NCT05499130 · Phase 2b · monotherapy | —All Cohorts (Cohort 1 & Cohort 2) NCT04996797 · Phase 2 · Ulcerative Colitis · phase 2 show 1 more result0%Cohort 1 Tulisokibart NCT04996797 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2 |
| Serious AEs | 0%1800 mga NCT05499130 · Phase 2b · monotherapy show 5 more results0%1800 mg NCT05499130 · Phase 2b · monotherapy 2.2%900 mg NCT05499130 · Phase 2b · monotherapy 2.2%900 mg NCT05499130 · Phase 2b · monotherapy 13%450 mg NCT05499130 · Phase 2b · monotherapy 0%450 mg NCT05499130 · Phase 2b · monotherapy | 1.1%All Cohorts (Cohort 1 & Cohort 2) NCT04996797 · Phase 2 · Ulcerative Colitis · phase 2 show 1 more result—Cohort 1 Tulisokibart NCT04996797 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2 |
| Most frequent reported AEs | 1800 mga eczema 33.3% (placebo 0%) influenza 33.3% (placebo 2.2%) proteinuria 33.3% (placebo 0%) NCT05499130 · Phase 2b · monotherapy show 5 more results1800 mg abnormal uterine bleeding 14.3% (placebo 0%) insomnia 14.3% (placebo 0%) anaemia 0% (placebo 2.2%) NCT05499130 · Phase 2b · monotherapy 900 mg nasopharyngitis 6.5% (placebo 6.5%) headache 2.2% (placebo 2.2%) vomiting 2.2% (placebo 4.3%) NCT05499130 · Phase 2b · monotherapy 900 mg headache 4.3% (placebo 2.2%) influenza 4.3% (placebo 2.2%) anaemia 2.2% (placebo 2.2%) NCT05499130 · Phase 2b · monotherapy 450 mg headache 8.7% (placebo 2.2%) anaemia 6.5% (placebo 2.2%) nasopharyngitis 4.3% (placebo 6.5%) NCT05499130 · Phase 2b · monotherapy 450 mg nasopharyngitis 6.4% (placebo 6.5%) upper respiratory tract infection 6.4% (placebo 4.3%) vomiting 6.4% (placebo 4.3%) NCT05499130 · Phase 2b · monotherapy | covid-19 5.6% (placebo 4.5%) NCT04996797 · Phase 2 · Ulcerative Colitis · phase 2 |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
duvakitug
show 1 more result
show 1 more result
tulisokibart
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
Crohn's Disease
Shared mechanism: TL1A · full Crohn's Disease pipeline
duvakitug
Developed by Teva Pharmaceutical Industries and partners
NCT05499130 · Phase 2b · completed
Randomized, double-blind, placebo-controlled dose-ranging basket study in UC and Crohn's disease. In UC the high dose separated from placebo on clinical remission (p=.003) and the low dose was borderline (p=.050); in Crohn's disease endoscopic response was 47.8% (high dose) and 26.1% (low dose) vs 13.0% placebo. The sponsor reports one-sided p-values at a 0.10 significance level, a lenient threshold, and each cohort was modest in size. A well-designed Phase 2b with a dose-dependent, partly borderline result is capped at moderate. Progressed to Phase 3.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: August 2028 · NCT07923383 (registry estimate)
Reported efficacy
Clinical remission (mMS) at week 14: UC cohort, clinical remission at week 14: 36% (450 mg) / 48% (900 mg) vs 20% placebo, placebo-adjusted 16% (p=.050) / 27% (p=.003). CD cohort, endoscopic response: 26.1% (low dose) / 47.8% (high dose) vs 13.0% placebo. P-values are one-sided at a 0.10 significance level. (met)
Result source: NCT05499130
tulisokibart
Developed by Merck & Co.
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: October 2028 · NCT06430801 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Crohn's Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | duvakitug | tulisokibart |
|---|---|---|
| Clinical remission (induction) | 54.3% vs 41.3%+13 vs placeboNCT054991303 other results
| —Trial running · NCT06651281 |
| Endoscopic response (induction) | 47.8% vs 13%+34.8 vs placeboNCT054991303 other results
| —Trial running · NCT06651281 |
| Clinical remission (maintenance) | —Trial running · NCT07184944 | —Trial running · NCT06651281 |
| Endoscopic response (maintenance) | —Trial running · NCT07184944 | —Trial running · NCT06651281 |
Clinical remission (induction)
- duvakitug
- 54.3% vs 41.3%+13 vs placeboNCT05499130
3 other results
- 37% vs 26.1% NCT05499130
- 50% vs 41.3% NCT05499130
- 37% vs 26.1% NCT05499130
- tulisokibart
- —Trial running · NCT06651281
Endoscopic response (induction)
- duvakitug
- 47.8% vs 13%+34.8 vs placeboNCT05499130
3 other results
- 26.1% vs 13% NCT05499130
- 39.1% vs 13% NCT05499130
- 34.8% vs 13% NCT05499130
- tulisokibart
- —Trial running · NCT06651281
Clinical remission (maintenance)
- duvakitug
- —Trial running · NCT07184944
- tulisokibart
- —Trial running · NCT06651281
Endoscopic response (maintenance)
- duvakitug
- —Trial running · NCT07184944
- tulisokibart
- —Trial running · NCT06651281
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. duvakitug: 4 of 4 rows · tulisokibart: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | duvakitug | tulisokibart |
|---|---|---|
| Dropout rate | 0%1800 mga NCT05499130 · Phase 2b · monotherapy show 5 more results0%1800 mg NCT05499130 · Phase 2b · monotherapy 8.5%900 mg NCT05499130 · Phase 2b · monotherapy 2.2%900 mg NCT05499130 · Phase 2b · monotherapy 19.6%450 mg NCT05499130 · Phase 2b · monotherapy 0%450 mg NCT05499130 · Phase 2b · monotherapy | —250 mga NCT05013905 · Phase 2 · registry result, not featured evidence show 2 more results—100 mg NCT05013905 · Phase 2 · registry result, not featured evidence 10.9%Induction Tulisokibart NCT05013905 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | 0%1800 mga NCT05499130 · Phase 2b · monotherapy show 5 more results0%1800 mg NCT05499130 · Phase 2b · monotherapy 2.1%900 mg NCT05499130 · Phase 2b · monotherapy 2.2%900 mg NCT05499130 · Phase 2b · monotherapy 8.7%450 mg NCT05499130 · Phase 2b · monotherapy 0%450 mg NCT05499130 · Phase 2b · monotherapy | —250 mga NCT05013905 · Phase 2 · registry result, not featured evidence show 2 more results—100 mg NCT05013905 · Phase 2 · registry result, not featured evidence —Induction Tulisokibart NCT05013905 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 0%1800 mga NCT05499130 · Phase 2b · monotherapy show 5 more results0%1800 mg NCT05499130 · Phase 2b · monotherapy 2.2%900 mg NCT05499130 · Phase 2b · monotherapy 2.2%900 mg NCT05499130 · Phase 2b · monotherapy 13%450 mg NCT05499130 · Phase 2b · monotherapy 0%450 mg NCT05499130 · Phase 2b · monotherapy | 22.2%250 mga NCT05013905 · Phase 2 · registry result, not featured evidence show 2 more results21.1%100 mg NCT05013905 · Phase 2 · registry result, not featured evidence 16.4%Induction Tulisokibart NCT05013905 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | 1800 mga eczema 33.3% (placebo 0%) influenza 33.3% (placebo 2.2%) proteinuria 33.3% (placebo 0%) NCT05499130 · Phase 2b · monotherapy show 5 more results1800 mg abnormal uterine bleeding 14.3% (placebo 0%) insomnia 14.3% (placebo 0%) anaemia 0% (placebo 2.2%) NCT05499130 · Phase 2b · monotherapy 900 mg nasopharyngitis 6.5% (placebo 6.5%) headache 2.2% (placebo 2.2%) vomiting 2.2% (placebo 4.3%) NCT05499130 · Phase 2b · monotherapy 900 mg headache 4.3% (placebo 2.2%) influenza 4.3% (placebo 2.2%) anaemia 2.2% (placebo 2.2%) NCT05499130 · Phase 2b · monotherapy 450 mg headache 8.7% (placebo 2.2%) anaemia 6.5% (placebo 2.2%) nasopharyngitis 4.3% (placebo 6.5%) NCT05499130 · Phase 2b · monotherapy 450 mg nasopharyngitis 6.4% (placebo 6.5%) upper respiratory tract infection 6.4% (placebo 4.3%) vomiting 6.4% (placebo 4.3%) NCT05499130 · Phase 2b · monotherapy | 250 mga crohn's disease 33.3% gastroenteritis 22.2% upper respiratory tract infection 16.7% NCT05013905 · Phase 2 · registry result, not featured evidence show 2 more results100 mg crohn's disease 36.8% upper respiratory tract infection 26.3% covid-19 15.8% NCT05013905 · Phase 2 · registry result, not featured evidence covid-19 12.7% urinary tract infection 9.1% anaemia 7.3% NCT05013905 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
duvakitug
show 3 more results
show 9 more results
show 3 more results
tulisokibart
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: duvakitug's landscape · tulisokibart's landscape